Background: Monoclonal antibodies known as biologic agents specifically targeted against interleukin-12 (IL-12), interleukin-17A (IL-17), and interleukin-23 (IL-23) have been the focus of research for moderate-to-severe chronic plaque psoriasis in recent years.Objectives: To discuss the immune-mediated model of psoriasis and to summarize current knowledge of the clinical efficacy and safety of new biologic agents for moderate-to-severe chronic plaque psoriasis.Methods: The PubMed database was searched for relevant articles on ustekinumab, briakinumab, tildrakizumab (MK-322), guselkumab, secukinumab, ixekizumab,Results: Fifty-five articles were identified. These studies suggest that the biologic agents specifically targeting IL-12, IL-17, and IL-23 are efficacious and safe in the treatment of moderate-to-severe psoriasis in adults.Conclusion: Current data from clinical trials suggest that biologic agents targeting IL-12, IL-17, and IL-23 are safe and efficacious drugs for use in moderate-to-severe chronic plaque psoriasis. Long-term data still need to be established.Contexte: Les anticorps monoclonaux connus pour ê tre des agents biologiques qui agissent spé cifiquement contre l'interleukine 12 (IL-12), l'interleukine 17A (IL-17) et l'interleukine 23 (IL-23) ont fait l'objet de recherche, au cours des derniè res anné es, en vue du traitement du psoriasis en plaques chronique, modé ré ou grave.Objectifs: L'é tude visait à examiner le modè le de psoriasis, mé dié par le systè me immunitaire, et à ré sumer les connaissances actuelles sur l'innocuité et l'efficacité clinique de nouveaux agents biologiques dans le traitement du psoriasis en plaques chronique,

Vitiligo is a common disorder of skin pigmentation resulting from autoimmune destruction of melanocytes. A variety of topical and systemic treatment options have been tried with varying success. Here we describe the case of a man with refractory vitiligo successfully treated with topical crisaborole ointment.Crisaborole ointment is a topical phosphodiesterase (PDE)-4 inhibitor recently FDA-approved for the treatment of atopic dermatitis. Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo.

No abstract

We present a case of a 39-year-old Hispanic woman who was referred to our clinic for treatment of several indurated plaques on her buttocks that developed one year prior to presentation, after she received injections of an unknown substance for augmentation. Biopsy of one nodule revealed silicone in the dermis.